EE200200267A - Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiinid ja nende kasutamine ravimina - Google Patents

Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiinid ja nende kasutamine ravimina

Info

Publication number
EE200200267A
EE200200267A EEP200200267A EEP200200267A EE200200267A EE 200200267 A EE200200267 A EE 200200267A EE P200200267 A EEP200200267 A EE P200200267A EE P200200267 A EEP200200267 A EE P200200267A EE 200200267 A EE200200267 A EE 200200267A
Authority
EE
Estonia
Prior art keywords
benzazocines
methano
hexahydro
medicaments
substituted
Prior art date
Application number
EEP200200267A
Other languages
English (en)
Inventor
Grauert Matthias
Carter Adrian
Weiser Thomas
Ensinger Helmut
Gaida Wolfram
Mierau Joachim
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of EE200200267A publication Critical patent/EE200200267A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
EEP200200267A 1999-11-27 2000-11-21 Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiinid ja nende kasutamine ravimina EE200200267A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19957156A DE19957156A1 (de) 1999-11-27 1999-11-27 Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
PCT/EP2000/011585 WO2001051471A1 (de) 1999-11-27 2000-11-21 Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
EE200200267A true EE200200267A (et) 2003-06-16

Family

ID=7930562

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200267A EE200200267A (et) 1999-11-27 2000-11-21 Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiinid ja nende kasutamine ravimina

Country Status (32)

Country Link
EP (1) EP1235809B1 (et)
JP (1) JP2003519687A (et)
KR (1) KR20020058042A (et)
CN (1) CN1177825C (et)
AR (1) AR026586A1 (et)
AT (1) ATE254108T1 (et)
AU (1) AU5789701A (et)
BG (1) BG106682A (et)
BR (1) BR0015786A (et)
CA (1) CA2383114C (et)
CO (1) CO5251469A1 (et)
CZ (1) CZ20022120A3 (et)
DE (2) DE19957156A1 (et)
DK (1) DK1235809T3 (et)
EA (1) EA005681B1 (et)
EE (1) EE200200267A (et)
ES (1) ES2210036T3 (et)
HR (1) HRP20020460A2 (et)
HU (1) HUP0204169A3 (et)
IL (1) IL149607A0 (et)
MX (1) MXPA02003822A (et)
NO (1) NO20022457D0 (et)
NZ (1) NZ519758A (et)
PL (1) PL355493A1 (et)
PT (1) PT1235809E (et)
SK (1) SK9302002A3 (et)
TR (1) TR200302031T4 (et)
UA (1) UA72566C2 (et)
UY (1) UY26448A1 (et)
WO (1) WO2001051471A1 (et)
YU (1) YU37902A (et)
ZA (1) ZA200204056B (et)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683089B2 (en) 2002-02-02 2004-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
DE10204276A1 (de) * 2002-02-02 2003-08-07 Boehringer Ingelheim Pharma N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
US10138207B2 (en) * 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121821A1 (de) * 1991-07-02 1993-01-14 Boehringer Ingelheim Kg Neue benzomorphane und ihre verwendung als arzneimittel
US5354758A (en) * 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19907874A1 (de) * 1999-02-23 2000-08-24 Boehringer Ingelheim Pharma N-(5-Phenyl-tetrahydrofuranyl)methyl- und N-(6-Phenyl-tetrahydropyranyl)methyl substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
UY26448A1 (es) 2001-06-29
ES2210036T3 (es) 2004-07-01
HUP0204169A3 (en) 2005-03-29
CA2383114A1 (en) 2001-07-19
PT1235809E (pt) 2004-04-30
AR026586A1 (es) 2003-02-19
ZA200204056B (en) 2003-07-30
HK1052176A1 (en) 2003-09-05
HUP0204169A2 (hu) 2003-03-28
EP1235809A1 (de) 2002-09-04
DK1235809T3 (da) 2004-03-15
BR0015786A (pt) 2002-08-13
HRP20020460A2 (en) 2003-10-31
NZ519758A (en) 2004-05-28
CN1177825C (zh) 2004-12-01
EA200200491A1 (ru) 2002-12-26
YU37902A (sh) 2005-07-19
ATE254108T1 (de) 2003-11-15
TR200302031T4 (tr) 2004-01-21
BG106682A (bg) 2003-01-31
NO20022457L (no) 2002-05-24
UA72566C2 (uk) 2005-03-15
CN1399630A (zh) 2003-02-26
NO20022457D0 (no) 2002-05-24
WO2001051471A1 (de) 2001-07-19
CA2383114C (en) 2008-06-17
CZ20022120A3 (cs) 2002-09-11
IL149607A0 (en) 2002-11-10
EP1235809B1 (de) 2003-11-12
DE50004455D1 (de) 2003-12-18
MXPA02003822A (es) 2002-12-13
AU5789701A (en) 2001-07-24
DE19957156A1 (de) 2001-05-31
PL355493A1 (en) 2004-05-04
EA005681B1 (ru) 2005-04-28
SK9302002A3 (en) 2002-11-06
KR20020058042A (ko) 2002-07-12
JP2003519687A (ja) 2003-06-24
CO5251469A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
EE200200175A (et) Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
EE03680B1 (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
EE200100009A (et) Bensimidasoolid, nende valmistamine ja kasutamineravimitena
EE200200064A (et) Arüülmetüülkarbonüülaminotiasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena
EE04151B1 (et) Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE05169B1 (et) Asendatud oksasolidinoonid ja nende kasutamine
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
LV12624A (lv) Thienylazolylalcoxyethanamines their preparation and their application as medicaments
HUP0102766A3 (en) Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
FI972629A7 (fi) Aryyli- ja heteroaryylisulfonamidijohdoksia, niiden valmistus ja niiden käyttö endoteliinin antagonisteina
EE200200160A (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
EE200100470A (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
EE200200342A (et) Asendatud 8-arüülkinoliinid, nende kasutamine, farmatseutiline kompositsioon ja prekursorühend
EE200100347A (et) 3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid
EE200000129A (et) Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiin-10-oolid, nende valmistamise meetod ja kasutamine ravimitena
HUP0300295A3 (en) Substituted benzamide derivatives, pharmaceutical compositions containing them and their use
FI953956A0 (fi) 2,3-rengaskondensoidut 1,4-dihydropyridiinit, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
NO20014692D0 (no) 3-amidinobenzensulfonamidderivater, medisinske sammensetninger inneholdende slike samt intermediater vedfremstillingen derav
FI971317A7 (fi) Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
IL149607A0 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3 benzazocines and the use thereof as medicaments
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
SI1235809T1 (sl) Substituirani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocini in njihova uporaba kot zdravila

Legal Events

Date Code Title Description
HD1A Correction of address